Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
JAK Inhibitors: Monitoring and Vaccination Recommendations for Immunosuppressed Patients
Description
The discussion focuses on JAK inhibitors and vaccination recommendations for immunosuppressed patients. It emphasizes the importance of counseling patients about vaccinations, adhering to CDC recommendations, and the varying side effect profiles of JAK inhibitors, particularly concerning infections, malignancies, and thromboembolic events. The speaker highlights black box warnings, especially regarding tofacitinib, and mentions accumulating pharmacovigilance data about long-term safety. Risks of viral infections and elevated lipid levels are stressed, alongside considerations for monitoring patients on these medications. The consensus guidelines suggest careful management of hematologic abnormalities, especially in older or cancer-prone patients. Vaccination guidelines are discussed, emphasizing the ideal timing for vaccinations before starting immunosuppression, the necessity of avoiding live vaccines during active immunosuppression, and the importance of keeping household members vaccinated. Overall, the presentation encourages awareness of safety updates for JAK inhibitors and systematic monitoring, alongside utilizing CDC resources for vaccination schedules tailored to immunosuppressed patients.
View moreConclusions
- JAK inhibitors are associated with significant risks such as serious infections, malignancy, and thrombotic events.
- The risk profile of JAK inhibitors varies based on their specificity, but predicting long-term effects remains difficult due to overlapping functions.
- Real-world data is crucial for understanding the long-term safety of JAK inhibitors, as clinical trials often exclude higher-risk patients.
- Monitoring recommendations for JAK inhibitors should be regularly updated based on evolving safety data and guidelines from relevant medical societies.
- Vaccination strategies for immunosuppressed patients on JAK inhibitors should prioritize the completion of vaccines before starting immunosuppressive therapy.
- Live vaccines should not be administered to patients while they are significantly immunosuppressed, and close contacts should also be vaccinated appropriately.
- Patients receiving JAK inhibitors require careful monitoring for hematologic changes and risks of serious infections.
- Higher rates of major adverse cardiovascular events were observed in patients treated with JAK inhibitors compared to those on TNF blockers.
- Regular skin examinations are recommended for patients on JAK inhibitors due to the increased risk of aggressive skin cancers.
- Michael Bonelli et al. Ann Rheum Dis 2024;83:139-160
- SR Ytterberg et al. NEJM 2022
- P. Nash et al ., Expert consensus statement on the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: 2024 update, Ann Rheum Dis (2025), https://doi.org/10.1016/j.ard.2025.01.032
- Wan J et al. J Allergy Clin Immunol Pract. 2023 Oct;11(10):3123-3132.e3. doi: 10.1016/j.jaip.2023.08.007. Epub 2023 Aug 10. PMID: 37572754.